Toga study gastric cancer
Webb23 nov. 2024 · In an open-label, single-arm, single-center, phase 2 trial (NCT02954536), patients with HER2-positive metastatic esophagogastric cancer received an induction cycle comprised of a flat dose of 200... WebbProgress is slow in targeted therapy research for gastric cancer, and overexpression of human epidermal growth factor receptor 2 (HER-2) may be an independent factor in the poor prognosis of gastric cancer. The T0GA study published in 2010 confirmed, for the first time, the effectiveness of trastuzumab in the treatment of advanced gastric ...
Toga study gastric cancer
Did you know?
Webbför 4 timmar sedan · Targeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction … Webb1 nov. 2024 · The anti-HER-2 monoclonal antibody, Trastuzumab, has been the only well-established cornerstone management for many years for advanced HER-2 positive gastric cancer. The landmark phase III ToGA trial [82] conducted in 2010 compared the efficacy of trastuzumab in combination with the standard first-line chemotherapy regimen at the …
Webb17 dec. 2011 · The Trastuzumab for Gastric Cancer (ToGA) study is the first international trial to include Japanese patients with human epidermal growth factor 2 (HER2) p … Webb20 maj 2013 · This analysis assessed treatment outcome according to tumor HER2 status (a pre-defined subgroup) and EGFR expression in EXPAND study pts, finding that pts with HER2 +ve tumors had a longer median overall survival. 4021 Background: In the EXPAND study adding cetuximab to first-line capecitabine and cisplatin chemotherapy (CT) failed …
WebbPrevious studies have reported that HER-2 protein expression level in those with gastric cancer was between 7.3% and 22.1%. 4 HER-2 expression in gastric cancer was more … WebbThis paper provides the most up-to-date practical guidance on HER2 testing and scoring in patients with gastric and gastro-esophageal junction cancer, as agreed by a panel of …
WebbStrong marketing professional with a Master of Science in Communication Studies focused in New Media and Society in Europe from Vrije ... Ph.D., is speaking at the kick-off meeting of the new European-wide project #TOGAS, "Towards gastric cancer… Our colleague, Marianna Vitaloni, Ph.D., is speaking at the kick -off meeting of ...
Webb4 dec. 2024 · The IMU-131 HERIZON study is based on the landmark ToGA study (Bang et. al., The Lancet, 2010) and included patients with HER2/neu overexpressing metastatic or advanced gastric/GEJ cancer who were naïve to HER2 therapy. Methods. Patients were randomized to IMU-131 plus standard chemotherapy or standard chemotherapy alone. jeffrey a fosterWebbSawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: A subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer. 2012 Jul;15(3):313-322. doi: 10.1007/s10120-011-0118-1 oxygen fractionationWebb17 maj 2024 · The TCGA analysis has posited four major molecular subgroups of gastric cancer: microsatellite instable (MSI), Epstein-Barr virus (EBV) associated, chromosomally instable (CIN), and genomically stable (GS) tumors. oxygen forms how many covalent bondsWebb16 feb. 2012 · In a large multicentric trial carried out on GC patients (ToGA study), a survival benefit of trastuzumab (herceptin) treatment in HER2-positive patients (IHC score 3+) has been shown [ 23 ]. Therefore, HER2 represents a promising therapeutic target. However the optimal HER2 testing strategy has not been defined yet. oxygen forms covalent bond with metalsWebbIntroduction. Metastatic ureteral tumors are difficult to diagnose pathologically. The only treatment is according to the primary disease, and the prognosis is generally poor. 1 We report a case in which metastatic gastric cancer was diagnosed by ureteroscopy and treated with radiotherapy as part of a multidisciplinary treatment program with a … oxygen found in natureWebbThe impulse came from the ToGA (Trastuzumab for Gastric Cancer) trial, a large, multicenter study that showed overall survival benefit in HER2-positive patients with advanced gastric cancer. In fact, the growing interest led to his working with a GI pathologist colleague, Christa Whitney-Miller, MD, to develop a joint presentation on the … oxygen free containers for riceWebbFurthermore, several biomarkers that will guide the development of novel therapeutic agents are emerging, potentially improving outcomes for some poor prognostic groups. In gastric cancer, the ToGA study is an example of a trial designed using selection by molecular marker, allowing the approval of anti-HER2 targeted agents in this histology. jeffrey a frey